(Q33451134)

English

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

R L Dobbins

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

R O'Connor-Semmes

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Kapur

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C Kapitza

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G Golor

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

I Mikoshiba

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

W Tao

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

E K Hussey

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

30 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

15-22

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Translating the A1C assay into estimated average glucose values

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Pathogenesis of bacteriuria in women with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Risk factors for symptomatic urinary tract infection in women with diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01462.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01462.X

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33451134&oldid=1536068903"